In the setting of type 2 diabetes (T2D), active PPARG increases insulin sensitivity by enhancing healthy adipogenesis and increasing production of adiponectin and GLUT4.49 As such, PPARG agonists like TZDs are standard in T2D therapy. Here, INS is linked to type 2 diabetes mellitus.